ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.

Jennifer A Foltz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.